Skip to main content
GutCited

Bifidobacterium breve для Irritable Bowel Syndrome (IBS)

D Исследования Существуют только предварительные исследования (лабораторные исследования, описания случаев).

Limited data from small studies. Preliminary evidence for symptom improvement.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dbifidobacterium\u002Dbreve\u0026condition\u003Dibs'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

D

Итог

Limited data from small studies. Preliminary evidence for symptom improvement.

Key Study Findings

Review
Compendium of Bifidobacterium-based probiotics: characteristics and therapeutic impact on human diseases.
Dose: None или: None Outcome: None Эффект: None None

Популяция: None

Other n=1098 8 weeks Open-label
A multicenter real-world, open-label study assessing the impact of a probiotic mixture on symptoms of …
Dose: None или: None (single-arm open-label) Outcome: Treatment success for abdominal pain and bloating Эффект: 73% pain, 81.9% bloating success at T1 <0.001

Популяция: IBS patients from 52 Italian gastroenterologists

Randomized Controlled Trial n=61 8 weeks Double-blind
Eight weeks of treatment with probiotic Bifidobacterium breve, Bif195 lowers fatigue scores in patients with …
Dose: None или: Placebo Outcome: IBS-SSS symptom severity score change Эффект: None None

Популяция: Patients with moderate-severe diarrhea-predominant IBS

Randomized Controlled Trial 4 weeks
Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group …
Dose: 2 g или: Placebo Outcome: Constipation symptoms Эффект: None P = 0.005

Популяция: IBS patients

Review
Postbiotics: A new member in the biotics family.
Dose: None или: None Outcome: Clinical applications overview Эффект: None None

Популяция: General population (review)

In Vitro
Bowel Inflammation and Nutrient Supplementation: Effects of a Fixed Combination of Probiotics, Vitamins, and Herbal …
Dose: None или: None Outcome: Colitis severity Эффект: None None

Популяция: Crohn's disease patients

Key Statistics

2

Исследования

150

Участники

↑

Positive

D

Оценка

Referenced Papers

Archivos argentinos de … 2024 3 цитирований
Revista espanola de … 2013 102 цитирований
Neurogastroenterology and motility 2010 213 цитирований
Journal of clinical … 2004 205 цитирований

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Часто используемые дозировки

general:
1-10 billion CFU/day
adultgisupport:
5-10 billion CFU/day
neonatalsupport:
1-5 billion CFU/day (as directed by pediatrician)

Верхний предел: Well-tolerated up to 10 billion CFU/day in clinical trials

Дозировки, изученные в исследованиях

Дозировка Длительность Эффект N
None -- Mixed --
None 8 weeks Positive 1098
None 8 weeks Neutral 61
2 g 4 weeks Mixed --
None -- Positive --
None -- Positive --
Serum-derived bovine immunoglobulin (SBI) -- Positive --
None -- Positive --

Лучшее время приёма: Before meals or on empty stomach; for infants, mix with breast milk or formula

Safety & Side Effects

Зарегистрированные побочные эффекты

  • ⚠ Mild gas during initial use
  • ⚠ Occasional loose stools in infants (transient)
  • ⚠ Rare abdominal discomfort
  • ⚠ Very rare: bacteremia in immunocompromised individuals

Известные взаимодействия

  • ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • ● Immunosuppressants (use with caution in immunocompromised patients)

Допустимый верхний уровень потребления: Well-tolerated up to 10 billion CFU/day in clinical trials

Всегда консультируйтесь с врачом перед началом приёма любых добавок.Всегда консультируйтесь с лечащим врачом перед началом приёма любой добавки.

Frequently Asked Questions

Does Bifidobacterium breve help with Irritable Bowel Syndrome (IBS)?
Based on 2 studies with 150 participants, there is preliminary evidence that needs more research that Bifidobacterium breve may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is D (Very Early Research).
How much Bifidobacterium breve should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bifidobacterium breve?
Reported side effects may include Mild gas during initial use, Occasional loose stools in infants (transient), Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bifidobacterium breve and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade D (Very Early Research). This rating is based on 2 peer-reviewed studies with 150 total participants. The overall direction of effect is positive.

References

  1. [1] Fabiana Bocchio et al.. Microbiome Res Rep. 2025. Compendium of Bifidobacterium-based probiotics: characteristics and therapeutic impact on human diseases. doi:10.20517/mrr.2024.52 PubMed
  2. [2] L Drago et al.. Benef Microbes. 2025. A multicenter real-world, open-label study assessing the impact of a probiotic mixture on symptoms of irritable bowel syndrome in adults. doi:10.1163/18762891-bja00097 PubMed
  3. [3] Ida Marie Bruun Grønbæk et al.. Front Nutr. 2025. Eight weeks of treatment with probiotic Bifidobacterium breve, Bif195 lowers fatigue scores in patients with diarrhoea-predominant irritable bowel syndrome: results … doi:10.3389/fnut.2025.1701341 PubMed
  4. [4] Mattia Tinazzi et al.. Yale J Biol Med. 2024. Bowel Inflammation and Nutrient Supplementation: Effects of a Fixed Combination of Probiotics, Vitamins, and Herbal Extracts in an In Vitro … doi:10.59249/JOMF5336 PubMed
  5. [5] Young Hoon Chang et al.. J Neurogastroenterol Motil. 2024. Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study. doi:10.5056/jnm23036 PubMed
  6. [6] María Del C Toca et al.. Arch Argent Pediatr. 2024. Postbiotics: A new member in the biotics family. doi:10.5546/aap.2023-10168.eng PubMed
  7. [7] Sabine Hazan et al.. Cureus. 2024. Gut Microbiome Alterations Following Oral Serum-Derived Bovine Immunoglobulin Administration in the Management of Dysbiosis. doi:10.7759/cureus.75884 PubMed
  8. [8] Han Chen et al.. J Transl Med. 2023. Alternation of the gut microbiota in irritable bowel syndrome: an integrated analysis based on multicenter amplicon sequencing data. doi:10.1186/s12967-023-03953-7 PubMed
  9. [9] Xinqi Chen et al.. Nutrients. 2023. Dose-Response Efficacy and Mechanisms of Orally Administered Bifidobacterium breve CCFM683 on IMQ-Induced Psoriasis in Mice. doi:10.3390/nu15081952 PubMed
  10. [10] Seung Yong Shin et al.. J Neurogastroenterol Motil. 2022. Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: … doi:10.5056/jnm21202 PubMed
  11. [11] Yae Jin Choi et al.. J Microbiol Biotechnol. 2022. Immunomodulatory Effects of Bifidobacterium spp. and Use of Bifidobacterium breve and Bifidobacterium longum on Acute Diarrhea in Children. doi:10.4014/jmb.2206.06023 PubMed
  12. [12] Edgar Torres-Maravilla et al.. Sci Rep. 2022. Serpin-positive Bifidobacterium breve CNCM I-5644 improves intestinal permeability in two models of irritable bowel syndrome. doi:10.1038/s41598-022-21746-8 PubMed
  13. [13] Carrie A M Wegh et al.. J Clin Gastroenterol. 2018. Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic Review. doi:10.1097/MCG.0000000000001054 PubMed
  14. [14] Hyuk Yoon et al.. J Clin Biochem Nutr. 2015. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a … doi:10.3164/jcbn.15-14 PubMed
  15. [15] María Ortiz-Lucas et al.. Rev Esp Enferm Dig. 2013. Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. doi:10.4321/s1130-01082013000100005 PubMed
  16. [16] Bong Ki Cha et al.. J Clin Gastroenterol. 2012. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, … doi:10.1097/MCG.0b013e31823712b1 PubMed
  17. [17] Eoin Barrett et al.. PLoS One. 2012. Bifidobacterium breve with α-linolenic acid and linoleic acid alters fatty acid metabolism in the maternal separation model of irritable bowel … doi:10.1371/journal.pone.0048159 PubMed
  18. [18] E O'Sullivan et al.. Benef Microbes. 2011. BDNF expression in the hippocampus of maternally separated rats: does Bifidobacterium breve 6330 alter BDNF levels? doi:10.3920/BM2011.0015 PubMed
  19. [19] D P McKernan et al.. Neurogastroenterol Motil. 2010. The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat. doi:10.1111/j.1365-2982.2010.01520.x PubMed
  20. [20] Anna Lyra et al.. BMC Gastroenterol. 2010. Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. doi:10.1186/1471-230X-10-110 PubMed
  21. [21] K Kajander et al.. Aliment Pharmacol Ther. 2007. Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. doi:10.1111/j.1365-2036.2007.03391.x PubMed
  22. [22] Kajsa Kajander et al.. Asia Pac J Clin Nutr. 2006. Clinical studies on alleviating the symptoms of irritable bowel syndrome. PubMed
  23. [23] K Kajander et al.. Aliment Pharmacol Ther. 2005. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. doi:10.1111/j.1365-2036.2005.02579.x PubMed
  24. [24] Alfredo Saggioro. J Clin Gastroenterol. 2004. Probiotics in the treatment of irritable bowel syndrome. doi:10.1097/01.mcg.0000129271.98814.e2 PubMed
  25. [25] P Brigidi et al.. Res Microbiol. 2001. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome … doi:10.1016/s0923-2508(01)01254-2 PubMed

Отказ от ответственности FDA: Данные утверждения не были оценены Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов (FDA). Продукты и информация на этом сайте не предназначены для диагностики, лечения, излечения или профилактики каких-либо заболеваний. Представленные оценки доказательности основаны на нашем анализе опубликованных рецензируемых исследований и не являются медицинской консультацией. Всегда консультируйтесь с лечащим врачом перед началом приёма любых добавок.